Survival of malignant lymphomas varies depending on the staging. In general, the 5-year survival rate for Hodgkin’s lymphoma is 31.9-90%; the 5-year survival rate for non-Hodgkin’s lymphoma is in the range of 26-73%.
Malignant lymphomas can be divided into two major groups, Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), based on histopathologic changes. In clinical work, the 5-year survival rate of patients with tumors is used to assess patient efficacy and prognosis.
The 5-year survival rate for Hodgkin’s lymphoma is more than 90% for stage I and II and 31.9% for stage IV. The 5-year survival rate for non-Hodgkin’s lymphoma ranges from 26-73%.
The treatment of malignant lymphoma is mainly radiotherapy and chemotherapy-based comprehensive treatment, and there will be different diagnosis and treatment plans according to the patient’s tumor stage, severity of the disease, physical fitness, etc., in order to achieve a cure or prolong the survival period and improve the quality of life.
To sum up, how long the patients with malignant lymphoma can live can not be generalized, it needs to be judged according to the patient’s own physical condition and the severity of the disease, and it is recommended to actively cooperate with the doctor’s treatment in order to improve the quality of life.